Vascular access use and outcomes: an international perspective from the Dialysis Outcomes and Practice Patterns Study

Jean Ethier, David C Mendelssohn, Stacey J Elder, Takeshi Hasegawa, Tadao Akizawa, Takashi Akiba, Bernard J Canaud, Ronald L Pisoni, Jean Ethier, David C Mendelssohn, Stacey J Elder, Takeshi Hasegawa, Tadao Akizawa, Takashi Akiba, Bernard J Canaud, Ronald L Pisoni

Abstract

Background: A well-functioning vascular access (VA) is essential to efficient dialysis therapy. Guidelines have been implemented improving care, yet access use varies widely across countries and VA complications remain a problem. This study took advantage of the unique opportunity to utilize data from the Dialysis Outcomes and Practice Patterns Study (DOPPS) to examine international trends in VA use and trends in patient characteristics and practices associated with VA use from 1996 to 2007. DOPPS is a prospective, observational study of haemodialysis (HD) practices and patient outcomes at >300 HD units from 12 countries and has collected data thus far from >35,000 randomly selected patients.

Methods: VA data were collected for each patient at study entry (1996-2007). Practice pattern data from the facility medical director, nurse manager and VA surgeon were also analysed.

Results: Since 2005, a native arteriovenous fistula (AVF) was used by 67-91% of prevalent patients in Japan, Italy, Germany, France, Spain, the UK, Australia and New Zealand, and 50-59% in Belgium, Sweden and Canada. From 1996 to 2007, AVF use rose from 24% to 47% in the USA but declined in Italy, Germany and Spain. Moreover, graft use fell by 50% in the USA from 58% use in 1996 to 28% by 2007. Across three phases of data collection, patients consistently were less likely to use an AVF versus other VA types if female, of older age, having greater body mass index, diabetes, peripheral vascular disease or recurrent cellulitis/gangrene. In addition, countries with a greater prevalence of diabetes in HD patients had a significantly lower percentage of patients using an AVF. Despite poorer outcomes for central vein catheters, catheter use rose 1.5- to 3-fold among prevalent patients in many countries from 1996 to 2007, even among non-diabetic patients 18-70 years old. Furthermore, 58-73% of patients new to end-stage renal disease (ESRD) used a catheter for the initiation of HD in five countries despite 60-79% of patients having been seen by a nephrologist >4 months prior to ESRD. Patients were significantly (P < 0.05) less likely to start dialysis with a permanent VA if treated in a faciity that (1) had a longer time from referral to access surgery evaluation or from evaluation to access creation and (2) had longer time from access creation until first AVF cannulation. The median time from referral until access creation varied from 5-6 days in Italy, Japan and Germany to 40-43 days in the UK and Canada. Compared to patients using an AVF, patients with a catheter displayed significantly lower mean Kt/V levels.

Conclusions: Most countries meet the contemporary National Kidney Foundation's Kidney Disease Outcomes Quality Initiative goal for AVF use; however, there is still a wide variation in VA preference. Delays between the creation and cannulation must be improved to enhance the chances of a future permanent VA. Native arteriovenous fistula is the VA of choice ensuring dialysis adequacy and better patient outcomes. Graft is, however, a better alternative than catheter for patients where the creation of an attempted AVF failed or could not be created for different reasons.

Keywords: DOPPS; arteriovenous fistulae; catheter; haemodialysis; vascular access.

Figures

Fig. 1
Fig. 1
(a) Trends in vascular access use (arteriovenous fistula, catheter or graft) at study entry in DOPPS I, II and III (1996–2007) among prevalent patient cross-sections in Japan, Italy, Germany, France and Spain. (b) Trends in vascular access use (arteriovenous fistula, catheter or graft) at study entry in DOPPS I, II and III (1996–2007) among prevalent patient cross-sections in Australia and New Zealand (ANZ) the UK, Belgium, Sweden, Canada and the United States.
Fig. 2
Fig. 2
Vascular access use by country among incident (incident patients entering DOPPS within 7 days of first-ever chronic dialysis; DOPPS II) haemodialysis patients.
Fig. 3
Fig. 3
The median time from referral to vascular access surgery by country based on the vascular access surgery questionnaire distributed among surgeons who placed more than one arteriovenous fistula or graft in prior 12 months. Model was adjusted for age, race, sex, 14 comorbidities and years on dialysis for patients on dialysis >180 days.
Fig. 4
Fig. 4
Average time between arteriovenous creation and cannulation by country based on answers from the Medical Director Survey, DOPPS II.

References

    1. Hoen B, Kessler M, Hestin D, et al. Risk factors for bacterial infections in chronic haemodialysis adult patients: a multicentre prospective survey. Nephrol Dial Transplant. 1995;10:377–381.
    1. Combe C, Pisoni RL, Port FK, et al. Dialysis Outcomes and Practice Patterns Study: data on the use of central venous catheters in chronic hemodialysis. Néphrologie. 2001;22:379–384.
    1. Feldman HI, Kobrin S, Wasserstein A. Hemodialysis vascular access morbidity. J Am Soc Nephrol. 1996;7:523–535.
    1. Dixon BS, Novak L, Fangman J. Hemodialysis vascular access survival: upper-arm native arteriovenous fistula. Am J Kidney Dis. 2002;39:92–101.
    1. Huber TS, Carter JW, Carter RL, et al. Patency of autogenous and polytetrafluoroethylene upper extremity arteriovenous hemodialysis accesses: a systematic review. J Vasc Surg. 2003;38:1005–1011.
    1. Pisoni RL, Young EW, Dykstra DM, et al. Vascular access use in Europe and the United States: results from the DOPPS. Kidney Int. 2002;61:305–316.
    1. NKF-KDOQI Clinical practice guidelines for vascular access: update 2000. Am J Kidney Dis. 2001;37(Suppl 1):S137–S181.
    1. Ethier JE, Lindsay RM, Barre PE, et al. Clinical practice guidelines for vascular access. Canadian Society of Nephrology. J Am Soc Nephrol. 1999;10(Suppl 13):S297–S305.
    1. NKF-KDOQI Clinical practice guidelines for vascular access. Am J Kidney Dis. 2006;48(Suppl 1):S248–S272.
    1. Tordoir J, Canaud B, Haage P, et al. European best practice guidelines (EBPG) on vascular access. Nephrol Dial Transplant. 2007;22(Suppl 2):ii88–ii117.
    1. Besarab A. Vascular access in Europe and the US: striking contrasts. Contemp Dial Nephrol. 1999;20:22–28.
    1. Stehman-Breen CO, Sherrard DJ, Gillen D, et al. Determinants of type and timing of initial permanent hemodialysis vascular access. Kidney Int. 2000;57:639–645.
    1. Young EW, Dykstra DM, Goodkin DA, et al. Hemodialysis vascular access preferences and outcomes in the Dialysis Outcomes and Practice Patterns Study (DOPPS) Kidney Int. 2002;61:2266–2271.
    1. O’Hare AM, Dudley RA, Hynes DM, et al. Impact of surgeon and surgical center characteristics on choice of permanent vascular access. Kidney Int. 2003;64:681–689.
    1. Sesso R, Yoshihiro MM. Time of diagnosis of chronic renal failure and assessment of quality of life in haemodialysis patients. Nephrol Dial Transplant. 1997;12:2111–2116.
    1. Arora P, Obrador GT, Ruthazer R, et al. Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center. J Am Soc Nephrol. 1999;10:1281–1286.
    1. Roubicek C, Brunet P, Huiart L, et al. Timing of nephrology referral: influence on mortality and morbidity. Am J Kidney Dis. 2000;36:35–41.
    1. Rayner HC, Pisoni RL, Gillespie BW, et al. Creation, cannulation and survival of arteriovenous fistulae: data from the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2003;63:323–330.
    1. Ravani P, Brunori G, Mandolfo S, et al. Cardiovascular comorbidity and late referral impact arteriovenous fistula survival: a prospective multicenter study. J Am Soc Nephrol. 2004;15:204–209.
    1. Young EW, Goodkin DA, Mapes DL, et al. The Dialysis Outcomes And Practice Patterns Study (DOPPS): an international hemodialysis study. Kidney Int. 2000;57(Suppl 74):S74–S81.
    1. Pisoni RL. Vascular access use and outcomes: results from the DOPPS. Contrib Nephrol. 2002;137:13–19.
    1. Centers for Medicare & Medicaid Services . 2006 Annual Report. Baltimore, Maryland: Department of Health and Human Services, Centers for Medicare & Medicaid Services, Office of Clinical Standards & Quality; End Stage Renal Disease Clinical Performance Measures Project. January 2007.
    1. Schwab S, Besarab A, Beathard G, et al. NKF-KDOQI clinical practice guidelines for hemodialysis vascular access. Am J Kidney Dis. 1997;30(Suppl 3):S137–S181.
    1. Tordoir JH, Mickley V. European guidelines for vascular access: clinical algorithms on vascular access for haemodialysis. EDTNA ERCA J. 2003;29:131–136.
    1. Fistula First Website Fistula First National Vascular Access Improvement Initiative: Change Concepts. Available at: . (Accessed 16 August 2007)
    1. Asif A, Unger SW, Briones P, et al. Creation of secondary arteriovenous fistulas: maximizing fistulas in prevalent hemodialysis patients. Semin Dial. 2005;18:420–424.
    1. Allon M, Robbin ML. Increasing arteriovenous fistulas in hemodialysis patients: problems and solutions. Kidney Int. 2002;62:1109–1124.
    1. Lok CE, Oliver MJ. Overcoming barriers to arteriovenous fistula creation and use. Semin Dial. 2003;16:189–196.
    1. Konner K. The initial creation of native arteriovenous fistulas: surgical aspects and their impact on the practice of nephrology. Semin Dial. 2003;16:291–298.
    1. Mendelssohn DC, Kua BT, Singer PA. Referral for dialysis in Ontario. Arch Intern Med. 1995;155:2473–2478.
    1. Mendelssohn DC, Ethier J, Elder SJ, et al. Haemodialysis vascular access problems in Canada: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS II) Nephrol Dial Transplant. 2006;21:721–728.
    1. Oliver MJ, Rothwell DM, Fung K, et al. Late creation of vascular access for hemodialysis and increased risk of sepsis. J Am Soc Nephrol. 2004;15:1936–1942.
    1. Canaud B, Leray-Moragues H, Kerkeni N, et al. Effective flow performances and dialysis doses delivered with permanent catheters: a 24-month comparative study of permanent catheters versus arterio-venous vascular accesses. Nephrol Dial Transplant. 2002;17:1286–1292.
    1. Tonelli M, Muirhead N. Access type as a predictor of dialysis adequacy in chronic hemodialysis patients. ASAIO J. 2000;46:279–282.
    1. Polkinghorne KR, McDonald SP, Atkins RC, et al. Vascular access and all-cause mortality: a propensity score analysis. J Am Soc Nephrol. 2004;15:477–486.
    1. Pastan S, Soucie JM, McClellan WM. Vascular access and increased risk of death among hemodialysis patients. Kidney Int. 2002;62:620–626.
    1. Di Iorio BR, Bellizzi V, Cillo N, et al. Vascular access for hemodialysis: the impact on morbidity and mortality. J Nephrol. 2004;17:19–25.
    1. Duncan ND, Singh S, Cairns TD, et al. Tesio-Caths provide effective and safe long-term vascular access. Nephrol Dial Transplant. 2004;19:2816–2822.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere